Fluticasone propionate/formoterol for COPD management: a randomized controlled trial

PURPOSE: To evaluate fluticasone propionate/formoterol (FP/FORM) in COPD. PATIENTS AND METHODS: COPD patients with forced expiratory volume in 1 s (FEV(1)) ≤50% predicted and ≥1 moderate/severe COPD exacerbation in the last 12 months were randomized to FP/FORM 500/20 or 250/10 µg bid, or formoterol...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Chron Obstruct Pulmon Dis
Main Authors: Papi, A, Dokic, D, Tzimas, W, Mészáros, I, Olech-Cudzik, A, Koroknai, Z, McAulay, K, Mersmann, S, Dalvi, PS, Overend, T
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2017
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5505160/
https://ncbi.nlm.nih.gov/pubmed/28740376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S136527
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki